Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Year: 2006
Type: article
Source: Blood
Authors: Mhairi Copland, Ashley Hamilton, Lucy J. Elrick, Janet W. Baird, Elaine K. Allan, Niove Jordanides, Martin Barow, Joanne C. Mountford, Tessa L. Holyoake
Institutions: Glasgow Royal Infirmary, University of Glasgow
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2149468947
